RSS Feed
- 6. Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance August 3, 2026Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance for the expanded indication of Rezūm™ Water Vapor Therapy, increasing the maximum prostate volume that can be treated with the device from 80 cm3 to 150 cm3 for patients with benign prostatic hyperplasia (BPH). Existing real-world and clinical trial data for Rezūm Therapy demonstrates […]
- 4. PAPZIMEOS was granted full approval August 3, 2026PAPZIMEOS was granted full approval by the US Food and Drug Administration (FDA) in August 2025, becoming the first and only approved therapy for the treatment of adults with RRP. Effective April 1, 2026, a new, permanent HCPCS Level II J-code (J3404 - injection, zopapogene imadenovec-drba suspension, per therapeutic dose) will be available for the […]
- 5. Dyne Therapeutics August 3, 2026Dyne Therapeutics shared positive topline results from its Phase 1/2 trial of the investigational drug, zeleciment rostudirsen (also known as DYNE-251), in individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The study met its primary endpoint, demonstrating a statistically significant increase in dystrophin from baseline at 6 months. Furthermore, the treatment maintained a […]
- 13. LivaNova August 3, 2026LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, has announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova's VNS Therapy™ System and its effectiveness on quality of life and daily function in […]
- Trump administration weighs overhaul of doctor payments in Medicare August 3, 2026The Trump administration is looking into alternatives to the current fee-for-service-based payment system for physicians who treat Medicare patients. The request for information issued on July 14 by the Centers for Medicare & Medicaid Services noted that the Current Procedural Terminology coding system, on which the Medicare reimbursement program is based, is owned by the […]
- 9. Gilead Sciences, Inc. August 3, 2026Gilead Sciences, Inc., a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the US Food and Drug Administration (FDA) has approved YEZTUGO® (lenacapavir) injection, 463.5 mg/1.5 mL. Click here for full Prescribing Information, including BOXED WARNING. Click here to learn more at YeztugoHCP.com.
- 11. NAMCP VBCC August 3, 2026NAMCP understands the changing landscape with regard to the delivery of healthcare moving from the traditional fee for service model to more of a focus on value based care and all of the complexities therein. The mission of the VBCC is to help payers and medical directors in their efforts to more effectively and efficiently […]
- US states are all over the map on how to regulate AI therapy chatbots August 3, 2026Millions of people now turn to AI chatbots the way they once would to a therapist, typing out their worst days to something that answers with warmth and confidence. The trouble starts when the bot plays doctor, handing out a diagnosis, a treatment plan or a license number it invented.
- Medicare update: New bill could ease mental health care access for millions August 3, 2026Millions of Medicare beneficiaries could gain faster access to mental health treatment under a newly introduced bipartisan bill in the Senate. The legislation, known as the Increasing Mental Health Options Act, was proposed by Senators John Kennedy of Louisiana, a Republican, and Martin Heinrich of New Mexico, a Democrat.
- Superagers keep youthful memories but their DNA does not explain why August 3, 2026Scientists expected SuperAgers might simply inherit fewer Alzheimer's-related risks, but their genes looked much like those of typical older adults. Their extraordinary memories may instead come from still-unknown protective forces involving the brain, body, lifestyle and environment.
